SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bill Evans who wrote (3983)5/17/1999 12:44:00 PM
From: Kingfisher  Read Replies (1) of 4891
 
Bill, their indeed seems to be an urgency that ADVR get Reticulose or associated derivatives to market. IMHO, the patent list that I posted [# 3982] gives an indication that another assumed-well-financed company most likely is already working at getting Reticulose to market.

In post #3982, I used the expression "use" patent in an attempt not to imply that any of the listed patents was specific to the granting of a patent for Reticulose itself. The Abbot and Squibb filings simply mention Reticulose in reference to their own drug in that Reticulose would be acceptable to use in conjunction with cocktails where their drug was the primary ingredient. Only the ADVR and IMM fillings expressly involve the use of Reticulose. This means only the ADVR and IMM patents actually are patents for specific uses of Reticulose.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News